...
首页> 外文期刊>Biological & pharmaceutical bulletin >2,3,22,23-Tetrahydroxyl-2,6,10,15,19,23-hexamethyl-6,10,14, 18-tetracosatetraene, an acyclic triterpenoid isolated from the seeds of Alpinia katsumadai, inhibits acyl-CoA: Cholesterol acyltransferase activity
【24h】

2,3,22,23-Tetrahydroxyl-2,6,10,15,19,23-hexamethyl-6,10,14, 18-tetracosatetraene, an acyclic triterpenoid isolated from the seeds of Alpinia katsumadai, inhibits acyl-CoA: Cholesterol acyltransferase activity

机译:2,3,22,23-四羟基-2,6,10,15,19,23-六甲基-6,10,14,18-四水三烯,一种从胜松高良种种子中分离出来的无环三萜,可抑制酰基辅酶A:胆固醇酰基转移酶活性

获取原文
获取原文并翻译 | 示例
           

摘要

In order to isolate a cholesterol-lowering compound from Alpinia katsumadai, an inhibitor for acyl-CoA: cholesterol acyltransferase (ACAT), an enzyme responsible for the cholesterol ester formation in liver, was purified, its chemical structure was determined, and in vivo and in vitro inhibition activities were performed. In a high fat diet mouse model, we discovered that the ethanol extract of Alpinia katsumadai reduced plasma cholesterol, triglyceride, and low density lipoprotein (LDL) levels. An acyclic triterpenoid showing ACAT inhibitory activity was isolated from the extract of seeds of A. katsumadai. By NMR spectroscopic analysis of its ~1H-NMR, ~(13)C-NMR, ~1H- ~1H correlation spectroscopy, heteronuclear multiple bond connectivity (HMBC), hetero multiquantum coherence (HMQC) and nuclear Overhauser effect, chemical structure of 2,3,22,23- tetrahydroxyl-2,6,10,15,19,23-hexamethyl-6,10,14,18-tetracosatetraene (1), were elucidated. The acyclic triterpenoid was found to be responsible for the ACAT inhibition activities of rat liver microsomes with IC _(50) values of 47.9μM. It also decreased cholesteryl ester formation with IC _(50) values of 26 μM in human hepatocyte HepG2 cell. The experimental study revealed that the ethanol extract of A. katsumadai has a hypolipemic effect in high fat diet mice, and the isolated acyclic triterpenoid has ACAT inhibition activity, showing a potential novel therapeutic approach for the treatment of hyperlipidemia and atherosclerosis.
机译:为了从Alpinia katsumadai分离出一种降低胆固醇的化合物,它是一种酰基辅酶A抑制剂:胆固醇酰基转移酶(ACAT),一种负责肝脏中胆固醇酯形成的酶,已确定其化学结构,并在体内和体内进行了研究。进行体外抑制活性。在高脂饮食的小鼠模型中,我们发现高良姜的乙醇提取物降低了血浆胆固醇,甘油三酸酯和低密度脂蛋白(LDL)的水平。从A.katsumadai的种子提取物中分离出显示出ACAT抑制活性的无环三萜。通过〜1H-NMR,〜(13)C-NMR,〜1H-〜1H相关光谱,异核多键连接性(HMBC),异质多量子相干性(HMQC)和核Overhauser效应的NMR光谱分析,化学结构为2阐明了,3,22,23-四羟基-2,6,10,15,19,23-六甲基-6,10,14,18-四异辛烯(1)。发现无环三萜类化合物负责大鼠肝微粒体的ACAT抑制活性,IC _(50)值为47.9μM。它还降低了人肝细胞HepG2细胞中IC_(50)值为26μM的胆固醇酯的形成。实验研究表明,胜松A.乙醇提取物对高脂饮食小鼠具有降血脂作用,而分离的无环三萜具有ACAT抑制活性,显示了一种治疗高脂血症和动脉粥样硬化的潜在新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号